Company: BFRG
Filing Date: 2025-08-08
Form Type: DEF 14A
Source: 0001641172-25-022671
Chunk: 14

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-08-08
Form: DEF 14A
Chunk 14
---
 6 |

<div align='center'>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE

FORTHIS PROPOSAL NO. 1.

EXECUTIVE OFFICERS OF THE COMPANY</div>

| Executive 
 Officers  |     | Position/Title                         |     | Age* |
| Vininder  
 Singh     |     | Chairman                               
 of the Board & Chief Executive Officer |     |   56 |
| Josh      
 Blacher   |     | Chief                                  
 Financial Officer                      |     |   53 |

* As of the date of this proxy statement.

The following is the biographical summary of our executive officers other than Mr. Singh, whose biographical summary is set forth above with the director nominees.

Mr. Vininder Singh.Please see description of Mr. Singh under “Election of Directors,” above.

Mr. Josh Blacherhas been the Chief Financial Officer of Bullfrog AI Holdings, Inc. since December 2024. Mr. Blacher has served as an employee of Danforth Advisors since September 2022, where he has worked as a chief financial officer in a consulting capacity for a number of life sciences companies as well as Managing Partner of Columbus Circle Capital LLC since August 2019. In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of Predictive Oncology since September 2023 as well as Rampart Bioscience and Excision Bio Therapeutics, among others. During his tenure at Columbus Circle Capital, Mr. Blacher has served as chief financial officer at several public and private companies. Prior to his tenure at Columbus Circle Capital, Mr. Blacher served as Chief Business Officer at Inmed Pharmaceuticals (Nasdaq: INM) from April 2018 to August 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts from Yeshiva University and a Master of Business Administration from Columbia Business School.

The Board has determined that Mr. Blacher is qualified for the position considering his career history and management experience in the Company and industry.

| 7 |

<div align='center'>SEC